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ABSTRACT 
This examination of the phenomena of polymorphism, the formation of different 
crystalline structures within the same chemical compound, is divided into two sections. 
The theory of polymorphism includes definitions and characteristics of polymorphs, 
mechanisms and conditions under which polymorphs form, and techniques for 
identifying and analyzing these polymorphs. The evaluation of a sulfur-containing 
pharmaceutical compound, sulfathiazole, by differential scanning calorimetry (DSC) for 
polymorph characteristics will be the focal point of this project. The effects of solvent 
and temperature, as well as the solubility of each compound, will be observed. Graphical 
data will be included to illustrate the transformations and melting points of each 
polymorph. 
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2. INTRODUCTION 
Polymorphs are molecules with the same chemical formula having different crystalline 
forms. The differences in crystalline forms have been known to occur as functions of 
solvent characteristics and thermodynamic aspects (enthalpy and free energy), although 
scientists have been unable to determine the exact nature and causes of polymorph 
formation within these parameters. Polymorphs are one of the many solid state 
characteristics a compound can have. "Solid state" simply refers to the phase of the drug 
compound (solid). 
Polymorphs of the same compound can have varying melting points and solubilities. A 
slight change in solubility can affect the bioavailability (uptake) ofa compound in the 
human body, so not coincidentally the evaluation of medicinal compounds for 
polymorphism is extremely important to the pharmaceutical industry. The multiple 
polymorphs of sulfathiazole (STZ) all have unique melting temperatures. Several 
polymorphs within one sample would show multiple transition states and melting points 
on a graph of temperature (in this case, power) versus time. Transition states occur as a 
polymorph sample shuffles its molecules to create new crystalline structures. 
At least five different polymorphs ofSTZ have been identified (1). The object of this 
work was polymorph screening of a model compound, STZ. The work consisted of 
studying the solubility of STZ in four different solvents, and recrystallizing it under 
different conditions (as a function of temperature). Various polymorphs of STZ were 
recrystallized. The crystals were analyzed using differential scanning calorimetry (DSC). 
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3. THEORY 
3.1 POLYMORPH SCREENING 
When a new drug is synthesized and submitted for approval to the Food and Drug 
Administration (FDA), the submitted application must contain some information on the 
solid state characteristics of the compound (2). Since the FDA does not regulate 
polymorph screening, many different techniques can be used to fulfill this requirement. 
The FDA does expect, however, that many tests using different solvents, concentrations, 
temperatures, and pH levels be performed on the compound prior to submission. Each 
polymorph discovered is subject to extensive physical and chemical property evaluations. 
3.2 SOLID STATE 
3.2.1 Amorphous and Crystalline Solids 
Solid pharmaceutical compounds exist in three forms: polymorphs, solvates, or 
amorphous forms (3). Amorphous compounds have no overall order to their molecular 
arrangement. Crystalline forms (those having an ordered structure and lattice within the 
molecule) of drug compounds are polymorphs and solvates. 
3.2.2 Polymorphs, solvates, and hydrates 
The ability of a substance to form more than one type of crystal is defined as 
polymorphism. The recognition of this phenomenon is especially important in the 
pharmaceutical industry, since one polymorph of a compound may prove to be a more 
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potent drug than any other crystalline form. Polymorphs exhibit the same chemical 
structure but different chemical and physical features; these characteristics are derived 
from the various crystal formations. Identification of a useful polymorph with revealing 
qualities is crucial to the development of an effective pharmaceutical drug. 
A pseudopolymorph forms when a molecule of solvent imbeds itself in the crystal 
structure (4). The pseudopolymorph is called a hydrate when the solvent is water. 
Pseudopolymorphs have variations in their physical and chemicals properties similar to 
that in normal polymorphs. 
Two categories of polymorphism define the types of crystals that form (3). 
Conformational polymorphism occurs when a relatively flexible molecule folds upon 
itself to form different arrangements; these arrangements subsequently bundle into 
crystals. Packing polymorphism happens when rigid molecules collect together to form 
three-dimensional crystals through intermolecular interactions. These interactions are 
defined as electronic contacts and hypothetical bonding between atoms of two or more 
molecules. 
3.2.3 Solid State Properties described by polymorphism 
Structural, chemical, electrical, mechanical, and dimensional solid state properties can 
affect the formation of polymorphs in drug compounds (4). The various effects of these 
properties add to the problem of identifying the main cause of polymorph formation in 
each drug sample. 
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3.3 FORMATION OF CRYSTALS 
3.3.1 Definitions 
The types of crystals that form in a given solvent are dependent on the solubility of the 
compound (5). Solubility ofa solid substance (the solute) is defined as the concentration 
of a solution where the solution phase is in equilibrium with the solid phase at a given 
temperature and pressure (3). This means that the solid is no longer dissolving, but it also 
is not recrystallizing. 
Solutions can be described in three ways (3). Undersaturation describes solutions where 
more solute is able to be dissolved. In other words, crystals will continue to dissolve 
completely in undersaturated solutions. Saturation is the state where the solid is in 
equilibrium with the solution. Crystals will neither dissolve nor recrystallize in saturated 
solutions. Supersaturation pertains to solutions that have more solid dissolved in them 
than the solution can hold. This state can be obtained by dissolving solute in the solvent 
at high temperatures, and then rapidly cooling the reaction vessel. Solutes may be 
precipitated from supersaturated solutions if the solution is disturbed, or if seed crystals 
are added to the solution. 
3.3.2 Crystal Growth 
Crystal growth begins with nucleation (3). Individual atoms or molecules collide as they 
randomly move in solution, and eventually amass into a small nucleus. The direction of 
nucleation can be influenced by seeding. Seeding involves introducing a seed crystal of a 
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known polymorph into a solution to drive the formation of that specific polymorph. 
Nuclei then collect more unit atoms or molecules to form crystals, either through 
conformational or packing polymorphism as described above (4). 
3.3.3 Crystal Defects 
Defects can occur as a result of the randomness of crystal formation. The defects are 
defined as sites of imperfection of packing of crystals (4). These defect sites are the most 
reactive and vulnerable parts of the polymorph. Vacancies in the crystal structure, twists, 
and edge defects are some of the most common crystal defects. 
3.4 POLYMORPfllSM OF SULFATHIAZOLE 
Sulfathiazole (STZ) has been studied thoroughly for polymorphs, and scientists have 
begun an extensive exploration of its solvates (5). Even though there has been some 
debate concerning the number of polymorphs of STZ, it is commonly understood that 
five polymorphs are produced upon recrystallization from a number of solvents. In 
Table 1 below the polymorphs of STZ are listed with pertinent information. Melting 
and transition temperatures are listed according to Kuhnert-Brandstiitter (1). 
Table 1. Characteristics of STZ Polymorphs 
Reference Code SUTHAZOI SUTHAZ SUTHAZ02 SUTHAZ04 SUTHAZ05 
Thenna\ Behavior M at 201°C T at l50-170°C Mat 173°C; Tat ---- M at 196°C 
(M = Melting) or 173°C ISO-175°C 
(T = Transition to 
SUTHAZOI) 
6 
3.5 METIIODS OF IDENTIFICATION AND ANALYSIS 
Many methods of identification and analysis have been developed to evaluate solid state 
drug compounds (3). X-ray crystallography and x-ray powder diffraction take advantage 
of the intensity and wavelength of x-rays to examine the internal structures of crystals. 
Microscopy can provide easy observation of phase changes, three-dimensional views of a 
crystal, and surface characteristics of solids on a molecular or atomic scale. Infrared 
spectroscopy (FT -IR) is especially sensitive to structure, environment, and conformation 
ofa compound, and therefore is a wonderful method for analyzing polymorphs. Solid-
state nuclear magnetic resonance (NMR) can analyze solids for the spatial arrangement of 
the carbon atoms in the crystal, as well as the environment of the solid. Thermal analyses 
such as differential scanning calorimetry (DSC) and thermogravimetric analysis (TGA) 
involve heating the sample and measuring any changes in its physical properties. TGA 
measures the change in mass of the sample as it is heated; DSC measures the change in 
enthalpy (heat, or power) to the sample as it is heated (6). 
4. EXPERIMENTAL 
4.1 MATERIALS AND METIIODS 
4.1.1 Compounds and Solvents 
A sulfur-containing compound, sulfathiazole (STZ), was examined for polymorphism. 
Four different solvents were used to create saturated solutions of STZ-n-propanol, 
acetone/chloroform mixture (1: I by volume), cool water, and hot water. These solvents 
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were randomly selected for their universal solvation characteristics, as well as their polar 
nature. This polar character may affect how crystals of STZ form. 
Table 2. List of Solvents and Abbreviations (for simplicity in future reference) 
SoLVENTS AND MIXTURES USED 
Cool Water (CW) 
Hot Water (HW) 
n-Propanol (N) 
Acetone/Chloroform Mixture 1:1 by Volume (AC) 
Table 3. Physical Properties of Solvents (7) 
SoLVENT MOLECULAR WEIGIIT DENSITY MEI,TlNG POINT 
(G/MOL) (G/CM) RANGEeC) 
n-Propanol 60.10 0.78505 -88.5 to -89.5 
Acetone 58.08 0.788 -94.0 
Chloroform 119.38 1.4476 -63.5 
Water 18.01 1.00 -4 to 0 
BOILING POINT 
RANGE(°C) 
82.5 
56.5 
61-62 
98-100 
Figure 4.1.1.. Three-dimensional space-jilling 
diagram of sulfathiazole created on SpartanBuild 
software (8). 
Figure 4.1.1b. One-dimensional diagram of 
sulfathiazole showing connectivity and double bond 
arrangement (9). 
STZ is one of many drugs classified as sulfonamides, or sulfa drugs. STZ is routinely 
used to treat bacterial infections, or to inhibit bacterial growth (10). 
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Table 4. Physical and Chemical Properties of Sulfathiazole (7) 
MOLECULAR WEIGHT (G/MOL) 255.32 
MELTING PoINT RANGE 202-202. 5°C 
SoLUBILITY 60 mg in 100 mL water at room temperature; 
also soluble in acetone, mineral acids, 
KOH and NaOH, ammonium hydroxide 
PHARMACEUTICAL PROPERTIES Antibacterial 
4.1.2 Recrystallization Techniques 
STZ (Aldrich Chemicals, batch #10316) was recrystallized according to the following 
procedural synopsis (11): 
(1) n-Propanol: Heat n-propanol to boiling (-95°C). Put approximately 1 gram of 
STZ in a small beaker, and add just enough hot n-propanol to dissolve 
completely. Small, white, cylinder-shaped crystals should fOITn as the solution 
cools. Collect crystals by vacuum filtration. 
(2) AcetonelChlorofoITn Mixture: Prepare a saturated solution of acetone and STZ. 
Dilute the solution with an equal amount of chloroform. Small, white crystals 
will form. Collect them by vacuum filtration. 
(3) Hot Water: Boil a supersaturated solution ofSTZ in water to dryness using a hot 
plate. As soon as evaporation is complete, place the white crystals in a hot air 
oven at 105°C. Take care not to overheat. 
(4) Cool Water: Recrystallize from water. Make a saturated solution, pour off 
solution into beaker, and place beaker in an ice bath. Collect crystals by vacuum 
filtration. 
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4.1.3 Method ofldentification and Analysis 
STZ crystals were heated in a Perkin-Elmer Pyris lOSe (serial #537NI032702), and 
transition states and melting temperatures were recorded by computer software (Pyris 
Thermal Analysis Software for Windows, Version 4.01, 2001). The DSe apparatus 
contains a heating element and two pans that hold samples. One pan contains the sample 
to be examined for polymorphs, along with a reference pan (blank) holding only air. 
Below is a schematic diagram of the differential scanning calorimeter (DSC). 
__ Thennoeouplto 
Figure 4.1.38. Schematic Diagram o/Differential Scanning Calorimeter (6). 
The DSe attempts to regulate the temperature in each sample as the crystals are heated 
and melt. This allows for an accurate reading of transition states and melting 
temperatures (6). Melting is an endothermic process, which means that an input of 
energy, heat, or power is required for the reaction to occur. The DSe delivered more 
power to the STZ sample as it melted to keep both sample temperatures the same. STZ 
was heated from 1400 e to 175°e with a rate oftwo to 10 degrees per minute (10). 
The software recorded the increase in power (in milliwatts [m W]) as peaks or endotherms 
on a graph over time. Sharp peaks indicate melting of crystals, while rounded hills 
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indicate transition stages. Polymorphs were identified by examining these plots, 
analyzing the temperatures at which transitions took place, and comparing the data values 
to the known values listed above in Table 1 under section 3.4. 
4.2 RESULTS 
4.2.1 Solubility of Sulfathiazole 
The solubility of sulfathiazole in the solvents varied. Solubility in water was poor, but 
somewhat better in hot water than cool water-as was to be expected, since solubility is a 
function of temperature. STZ dissolved well in acetone; the level of solubility in n-
propanol was slightly less than that in acetone/chloroform. There was some resistance of 
sulfathiazole to continue its level of solubility in the acetone/chloroform mixture once 
chloroform was added to the mixture. 
4.2.2 The Effect of Solvent 
The effect of solvent on polymorph formation was dramatic. As Table 5 shows, the types 
ofpolymorphs formed varied widely among the solvents used. Please see Thermograms 
A-D on pages 13-16 for data. Each thermogram displays a different plot of heat flow 
(mW) versus temperature for each of the samples. The large endotherm at the far right of 
all graphs indicates the melting point of the most stable compound, SUTHAZO 1. Each 
graph has this same endotherm, indicating that each sample ultimately contains the same 
compound after all transitions. Interestingly, the plots also contain smaller endotherms. 
The lesser endotherms at varying temperatures indicate transformations between 
polymorphs. 
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Sulfathiazole 
Thermograms A-D show the transitions and melting points of STZ. Both graphs A (n-
propanol) and B (acetone/chloroform) show strong, even baselines and definite peaks (at 
204.295 and 203.461 0 C respectively), indicating the melting ofSUTHAZOI. No 
transition peaks are shown in either trial of n-propanol or acetone/chloroform. 
Thermograms C and D differ from the data given by n-propanol and acetone/chloroform, 
and also from each other significantly-although they are from the same solvent, water. 
Thermogram C (cool water) shows a transition endotherm at 165.642°C and a melting 
endotherm ofSUTHAZOI at 202.757°C. According to Table 5, the transition endotherm 
could result from either SUTHAZ or SUTHAZ02 transforming to SUTHAZOI. 
Thermogram D (hot water) best depicts multiple polymorph presence. The small 
transition endotherm at 161.993°C is most likely the result of the transformation of 
SUTHAZ or SUTHAZ02. The second, larger endotherm at 199.656°C is peculiar, and 
indicates the transition of SUTHAZ05. After all transitions have taken place, the melting 
endotherm ofSUTHAZOl follows at 204.563°C. 
Table 5. Thermal Behavior of STZ Samples 
GRAPH 1'" TRANsmoN 2"" TRANSITION MELTING 
A (N-PROPANOL) None None 204.295°C 
B (ACETONE/CHLOROFORM) None None 203.461°C 
C (COOL WATER) 165.642°C; from None 202.757°C 
either SUTHAZ or 
SUTHAZ02to 
SUTHAZOI 
D(HOTWATER) 161.993°C; from 199.656°C; from 204.563°C 
either SUTHAZ or SUTHAZ05to 
SUTHAZ02to SUTHAZOI 
SUTHAZOI 
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4.1.1 The Effect of Temperature 
It is interesting to note that water at different temperatures recrystallized the sulfathiazole 
samples with different polymorphs. Hot water could have recrystallized up to four 
different polymorphs: SUTHAZ, SUTHAZ01, SUTHAZ02, and SUTHAZ05. Cold 
water could have only recrystallized three: SUTHAZ, SUTHAZ01, and SUTHAZ02. 
5. CONCLUSION 
DSC analysis of sulfathiazole showed that at least 4 polymorphs of STZ exist in 
recrystallized samples. The organic solvents used in this experiment, n-propanol and 
acetone/chloroform, produced a single polymorph. Water, at different temperatures, 
produced varying numbers ofpolymorphs of STZ. Of the four solvents used, the best 
polymorph formation was found in the hot water sample. Perhaps the differences in 
crystalline forms, functioning as elements of solvent characteristics and thermodynamic 
aspects (change in heat and free energy), as addressed in the Introduction, caused varying 
polymorph formation within the same solvent. 
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ApPENDIX 
Coding Chart of All Experimental Combinations 
NST NSN 
ACST ACSN 
CWST CWSN 
HWST HWSN 
XXYY 
xx = Solvent (N = n-propanol, AC = acetone/chloroform, CW = cool water, HW = hot 
water) 
YY = Compound (ST = sulfathiazole, SN = sulfanilamide) 
Thermograms 
Thermogram data is provided on pages 13-16. All transitions and peaks are labeled with 
the appropriate polymorph identification. Axes of graph: Heat Flow (mW) vs. 
Temperature eC). 
Thermogram A, p. 13 - Polymorphism of STZ in n-propanol 
Thermogram B, p. 14 - Polymorphism ofSTZ in acetone/chloroform mixture (1:1) by 
volume 
Thermogram C, p. 15 - Polymorphism of STZ in cool water 
Thermogram D, p. 16 - Polymorphism of STZ in hot water 
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